Results 161 to 170 of about 31,699 (207)

Development and Validation of an LC-MS/MS Method for Simultaneous Determination of 12 Antibiotics in Human Serum. [PDF]

Infect Drug Resist
Ruan S, Wang J.
europepmc   +1 more source

Carbapenem Resistance at the Crossroads: A New Therapeutic Era for Critical Care. [PDF]

Indian J Crit Care Med
Prakash J.
europepmc   +1 more source

Sulbactam-durlobactam and cefiderocol combination treatment of <i>Burkholderia cenocepacia</i>-associated Fitz-Hugh-Curtis syndrome. [PDF]

Antimicrob Agents Chemother
Gaglani B, Andermann TM, Wate C, Oldan J, Desai CS, Marshall SH, Bonomo RA, Coakley R, van Duin D, Lachiewicz A.   +9 more
europepmc   +1 more source

Antimicrobial activity of sulbactam-durlobactam against <i>Acinetobacter baumannii-calcoaceticus</i> complex strains causing non-respiratory and non-bloodstream infections from the United States (2023-2025). [PDF]

Microbiol Spectr
Cyr E, Argotsinger J, Beck ET, Chamberland RR, Clark AE, Daniels AR, Liesman R, Fisher M, Gialanella P, Hand J, Harrington AT, Humphries RM, Huse H, Hamilton-Seth R, Hankins JD, Kufel WD, Riddell SW, Mehta M, Demkowicz R, Mochon AB, Salimnia H, Khan A, Pierce VM, Potula R, Tekle T, Simner PJ, Tibbetts RJ, Vu C, Abbo LM, Martinez O, Dumm RE, Mutnal MB, Jenkins TC, Chávez V, Pinargote P, Bowling J, Munson E, Zurawski DV, Nicolau DP, Asempa TE, Acinetobacter baumannii Complex National Biorepository (ACNBio) Study Group.   +40 more
europepmc   +1 more source

Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistant <i>Acinetobacter baumannii</i> infections (intracranial, pulmonary, and bloodstream) in a post-trauma adolescent female: a case report. [PDF]

Front Med (Lausanne)
Lu J, Zhong J, Qiu W, Zhang Q.
europepmc   +1 more source

Multidrug-resistant Acinetobacter spp. bloodstream infections in hematologic patients: clinical characteristics, genomic features, and eravacycline-based combination therapy. [PDF]

BMC Infect Dis
Guo W, Li J, Yang N, Zhen S, Zhang T, Lin Q, Cao Y, Cao W, Pang A, Yang D, Chen X, Zhang R, Wei J, Ma Q, Zhai W, He Y, Zheng Y, Jiang E, Han M, Feng S.   +19 more
europepmc   +1 more source

Differences and trends in pathogens between ventilator-associated pneumonia and non-ventilator-associated pneumonia: data from 61 hospitals in Suzhou, China, 2020-2024. [PDF]

BMJ Open
Yang J, Song X, Wang Y, Zhang J, Jin M.
europepmc   +1 more source

Tracheal Actinomycosis Presenting as a Pseudotumor: A Case Report. [PDF]

Cureus
Velásquez-Salazar M, Aguilar Díaz CD.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sulbactam / Ampicillin

Infection Control and Hospital Epidemiology, 1988
Sulbactam/ampicillin was recently marketed for use in several infections caused by beta-lactamase-producing organisms. Sulbactam is the second beta-lactamase inhibitor to become available in the United States. Interest in inhibition of beta-lactamases arose in the late 1960s when a combination consisting of an antibacterial agent and an enzyme ...
openaire   +1 more source

Ampicillin/sulbactam

Reactions Weekly, 2023
  +4 more sources